CORRECTED: Par Pays $100M To Settle Suit Over Generic Heartburn Drug

By Daniel Siegal (September 22, 2014, 5:10 PM EDT) -- Par Pharmaceutical Cos. has agreed to pay $100 million to Salix Pharmaceuticals Inc. unit Santarus Inc. and the University of Missouri to resolve claims Par's generic version of the heartburn drug Zegerid infringed the university's patents, according to a Monday filing with the Securities and Exchange Commission....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!